Join us this fall at the Knight Campus Entrepreneurship Speaker Series lecture, "Navigating the Medical Device Approval Process," featuring Srinidhi (Srin) Nagaraja on Tuesday, October 8th from 10:00 am - 11:00 am in the Knight Campus 1st floor Beetham Family Seminar Room. For those unable to attend in person, Zoom webinar details will be available on our events website closer to the lecture date.

About the Talk: Srinidhi (Srin) Nagaraja, Technical Fellow at G.RAU Inc., will discuss the medical device regulatory landscape in US and international markets. The talk will highlight recent changes in regulations that are particularly important for early venture companies seeking to bring a device to market.

About Srinidhi Nagaraja: Srinidhi Nagaraja is a technical fellow at G.RAU, Inc. with over 20 years of experience in the biomedical field. He has expertise in mechanical and corrosion behavior of implantable medical products and is the author of more than 100 scientific publications and presentations. Nagaraja has served as principal or co-principal investigator on numerous medical device research studies and has faculty appointments at Catholic University, University of Maryland, and Uniformed Services University of the Health Sciences. He received his Ph.D. in Mechanical Engineering from the Georgia Institute of Technology and holds an M.S. from Georgia Tech and a B.S. from the University of Michigan, both in Mechanical Engineering.

Join us this fall at the Knight Campus 2024 Distinguished Lecture Series, "Engineering of T Cell Cancer Therapies," featuring David Mooney on Wednesday, November 6 from 3-4pm in the Knight Campus Beetham Family Seminar Room. An in-person networking reception will follow in the seminar pre-function space immediately after the lecture. Visit our event website to submit your RSVP! 

For those unable to attend in person, Zoom webinar details will be posted to our events website closer to the lecture date. 

About the Talk: In his talk, David Mooney will discuss how T cell-based therapies are revolutionizing the treatment of some types of cancer, but currently suffer from a number of limitations. To address these challenges, researchers are developing biomaterials capable of concentrating, interrogating, and manipulating stem and immune cells ex vivo and in the body by controlling, in space and time, the interaction of the cells with various immunomodulatory cues. Therapeutic cancer vaccines and the development of artificial antigen presenting cells for the manufacturing and in vivo boosting of adaptive T cell-based therapies will be highlighted. 

About David Mooney: David Mooney is the Robert Pinkas Family Professor of Bioengineering and a core faculty member in Harvard University's School of Engineering and Applied Sciences and Wyss Institute for Biologically Inspired Engineering. He is also a member of the Knight Campus External Advisory Board, as well as several national academies, and has won numerous awards for his research and his mentorship/teaching. To learn more about David Mooney, view his bio on the External Advisory Board web page.